| Title |
Secondary Stroke Prevention in Cryptogenic Stroke and Embolic Stroke of Undetermined Source (ESUS)
|
|---|---|
| Published in |
Current Neurology and Neuroscience Reports, July 2017
|
| DOI | 10.1007/s11910-017-0775-5 |
| Pubmed ID | |
| Authors |
Hans-Christoph Diener, Richard Bernstein, Robert Hart |
| Abstract |
The purpose of the study was to review the literature on cryptogenic stroke and embolic stroke of undetermined stroke (ESUS). Cryptogenic stroke according to TOAST criteria is a stroke which is not due to cardiogenic embolism, small vessel disease with lacunes or large vessel disease of brain supplying arteries. In the context of secondary stroke prevention studies, cryptogenic stroke is not operationally defined. The new concept of "embolic stroke of undetermined source" (ESUS) provides an operational definition. ESUS is diagnosed as a non-lacunar stroke on cerebral imaging and exclusion of large vessel atherosclerosis by CTA, MRA or ultrasound. Cardiogenic embolism is made less likely by ECG monitoring and echocardiography. At present, aspirin is used for secondary stroke prevention in patients with cryptogenic stroke. Based on the construct that ESUS might be caused by undetected atrial fibrillation or other embolic mechanisms, ongoing randomised secondary stroke prevention trials are comparing non-vitamin K oral anticoagulants (NOACs) with aspirin. |
Mendeley readers
The data shown below were compiled from readership statistics for 106 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 106 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 14% |
| Student > Master | 12 | 11% |
| Researcher | 11 | 10% |
| Other | 10 | 9% |
| Student > Bachelor | 8 | 8% |
| Other | 23 | 22% |
| Unknown | 27 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 46 | 43% |
| Neuroscience | 9 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Nursing and Health Professions | 2 | 2% |
| Other | 7 | 7% |
| Unknown | 34 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 June 2018.
All research outputs
#8,028,575
of 24,135,931 outputs
Outputs from Current Neurology and Neuroscience Reports
#429
of 956 outputs
Outputs of similar age
#121,320
of 315,948 outputs
Outputs of similar age from Current Neurology and Neuroscience Reports
#12
of 20 outputs
Altmetric has tracked 24,135,931 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 956 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,948 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.